The Rising Prevalence of Chronic Traumatic Encephalopathy Market will drive Increased Adoption of Diagnostic Tools
Chronic traumatic encephalopathy (CTE) is a degenerative brain disease caused by repeated head injuries and concussions. It can only be diagnosed reliably during an autopsy by examining brain tissue for a buildup of an abnormal protein called tau. Over time, these tau proteins clump together around blood vessels throughout the brain tissue, slowly squeezing off nerve cells. This deterioration eventually ruins neuronal connections and leads to cognitive and psychiatric issues such as memory loss, confusion, impaired judgment, impulse control problems, aggression, depression and, eventually, progressive dementia. CTE is known to develop in athletes participating in contact sports like football, hockey, wrestling, mixed martial arts and boxing, due to repetitive brain trauma.
The chronic traumatic encephalopathy market is estimated to be valued at USD 958 million in 2024 and is expected to reach USD 1,480 million by 2031, growing at a compound annual growth rate (CAGR) of 6.4% from 2024 to 2031.
Key Takeaways
Key players operating in the chronic traumatic encephalopathy market are Pfizer, Lilly, Johnson & Johnson, Biogen among others. These players are involved in developing novel therapeutic drugs and diagnostic tools to detect CTE at an early stage.
The increasing popularity of contact sports and awareness regarding the mental health risks associated with repetitive brain injuries is driving the demand for CTE diagnostics and therapeutics. As per statistics, around 10-20% of athletes participating in contact sports are at the risk of developing long-term neurological complications.
Chronic Traumatic Encephalopathy Market technological advancements are being made to develop novel PET imaging agents, blood and fluid biomarkers to non-invasively diagnose CTE in living patients. Biomarkers can help detect the protein deposits in the brain at an early asymptomatic stage to help manage the condition better. MRI and CT imaging techniques are also being optimized to detect structural changes in the brain caused by CTE.
Market Trends
Development of novel PET tracers - Several research projects are ongoing to develop positron emission tomography (PET) imaging agents to detect tau deposits in living patients. These tracers would enable early diagnosis of CTE.
Blood and fluid biomarkers - Biomarkers detected in cerebrospinal fluid or blood can potentially diagnose CTE in asymptomatic individuals. Companies are developing assays to detect tau and other protein biomarkers linked to the disease.
Market Opportunities
Therapeutics targeting tauopathies - Due to absence of approved drugs, an opportunity exists for companies to develop disease-modifying therapies targeting tau through immunotherapy, gene-silencing, or other novel mechanisms.
Wearable sensors - Integration of wearable sensors in helmets and mouthpieces during contact sports can monitor head impacts in real-time. Data generated can help in modeling risk of CTE and its progression.
Impact of COVID-19 on Chronic Traumatic Encephalopathy Market Growth
The COVID-19 pandemic has greatly impacted the chronic traumatic encephalopathy (CTE) market. During the initial lockdown phases in 2020, there was a steep decline in the number of new CTE cases diagnosed. This can be attributed to the cancellation or postponement of contact sports activities and events which are a leading cause of repetitive brain trauma linked to CTE. There was also decreased access to healthcare facilities for symptoms evaluation and testing amid lockdowns. However, with resumption of sports in 2021, new diagnoses have started increasing gradually but are still below pre-pandemic levels. Social distancing norms have led to alterations in sports practices to minimize risks but various leagues and associations are ensuring regular testing of players to track long-term effects of COVID-19 on the brain. Telemedicine has played a key role for remote CTE consultations and symptom monitoring during lockdowns. Players have been advised about risks of multi-system effects of COVID-19 and importance of following safety protocols even after vaccination. Advancements in blood and fluid biomarkers hold promise for non-invasive CTE diagnosis offering opportunities amid pandemic-driven healthcare changes. Awareness initiatives regarding long-term neurological implications and safety guidelines continue online and via social media. While the pandemic has caused short-term decline, focus on innovation and digitalization is expected to support mid-to-long term market recovery and growth.
North America accounts for the largest share of the CTE market in terms of value. This can be attributed to rising prevalence of contact sports-related brain injuries, increasing diagnosis rates supported by advanced research labs, presence of major players and ongoing clinical trials for CTE treatments in the US and Canada. Europe is the second largest CTE market led by Germany, UK and France. Higher acceptance of CTE as a distinct disease, growing focus on sports concussion management and collaborations between research institutes and sporting bodies are driving growth. Asia Pacific region is projected as the fastest growing market for CTE supported by rising health expenditures, large patient pools, improving access to diagnostic tests and emergence of specialized neurological centers in China, Japan and India. Increasing integration of wearable sensors and digital platforms in sports is anticipated to further fuel the Asia Pacific CTE market expansion in coming years.
Get More Insights On- Chronic Traumatic Encephalopathy Market
Get This Report in Japanese Language: 慢性外傷性脳症市場
Get This Report in Korean Language: 만성 외상성 뇌병증 시장
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc.
(https://www.linkedin.com/in/ravina-pandya-1a3984191)
Comments
0 comment